K. Kerr

Oncology · 2017–2018

A researcher in the Science corpus: 3 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom K. Kerr trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Wolchok (in Oncology)

Papers from K. Kerr's perspective

Ordered by how strongly the researchers K. Kerr trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
  2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  3. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (Clinical Cancer Research)
  4. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (New England Journal of Medicine)
  5. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
  6. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (New England Journal of Medicine)
  7. Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer (New England Journal of Medicine)
  8. Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma (New England Journal of Medicine)
  9. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. (Annals of Oncology)
  10. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis (Nature Communications)

Their papers